Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 10A inhibitor, PDM‐042 [(E)‐4‐(2‐(2‐(5,8‐dimethyl‐[1,2,4]triazolo[1,5‐a]pyrazin‐2‐yl)vinyl)‐6‐(pyrrolidin‐1‐yl)pyrimidin‐4‐yl)morpholine] in rats: potential for the treatment of schizophrenia

Recently, we identified a novel phosphodiesterase 10A (PDE10A) inhibitor, PDM‐042 ((E)‐4‐(2‐(2‐(5,8‐dimethyl‐[1,2,4]triazolo[1,5‐a]pyrazin‐2‐yl)vinyl)‐6‐(pyrrolidin‐1‐yl)pyrimidin‐4‐yl)morpholine). PDM‐042 showed potent inhibitory activities for human and rat PDE10A with IC (50) values of less than...

Descripción completa

Detalles Bibliográficos
Autores principales: Arakawa, Keita, Maehara, Shunsuke, Yuge, Natsuko, Ishikawa, Makoto, Miyazaki, Yutaka, Naba, Hiroyasu, Kato, Yutaka, Nakao, Kazunari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242175/
https://www.ncbi.nlm.nih.gov/pubmed/28116094
http://dx.doi.org/10.1002/prp2.241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242175/
https://www.ncbi.nlm.nih.gov/pubmed/28116094
http://dx.doi.org/10.1002/prp2.241

Ejemplares similares